AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$ANGO

AngioDynamics Shares Fall 4.3% Despite Q1 Earnings Beat and Strong Med Tech Growth

AngioDynamics (ANGO) reported Q1 fiscal 2027 earnings with revenue of $80.9M, beating estimates, driven by 13.2% growth in Med Tech. Adjusted loss was $0.04 per share, narrower than expected. Shares fell 4.3% pre-market despite results, possibly due to tariff refund impact on margins and unchanged guidance.

Original reporting
finance.yahoo.com
Published Oct 8, 2026, 12:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 12:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AngioDynamics Shares Fall 4.3% Despite Q1 Earnings Beat and Strong Med Tech Growth — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ANGOBearishMed
01

Why it matters

Earnings beat did not translate into price appreciation; investors focus on margin quality and unchanged outlook, leading to a pre‑market sell‑off.

02

Market read

First‑report earnings data for a small‑cap med‑tech company; modest impact on broader market, but relevant for sector specialists.

03

What to watch

Tariff refund boost to gross margin may be non‑recurring; future quarters could see margin compression without such refunds.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

AngioDynamics reported Q1 FY2027 results with revenue slightly above estimates, a narrowed loss, and reaffirmed full‑year guidance. Leadership transition announced for November.

Company-level read

Ticker impact

$ANGOBearishHigh confidence
Context

Q1 fiscal 2027 earnings beat expectations but shares fell 4.3% pre‑market; guidance unchanged.

Expected impact

likely further downside as market questions margin quality and unchanged outlook

Evidence & confidence

Earnings beat was modest and margin boost included tariff refunds; unchanged guidance fails to excite investors, prompting a sell‑off.

Market effects

Sector

MedTech segment shows strong growth, may benefit peers with similar product lines.

Regional

U.S. small‑cap healthcare sector could see modest pressure.

Global

Limited; impact confined to niche medical‑technology space.

Counterpoint

What could challenge this read

The earnings beat and double‑digit Med Tech growth could be a buying opportunity if the market overreacts to the short‑term price dip.

Key entities

  • Company
    AngioDynamics Inc.

    Medical technology firm reporting Q1 FY2027 results.

  • Executive
    Eric Honroth

    Incoming CEO effective November 2026.

Read at source← All news

StoryAngioDynamics posts Q1 FY2027 earnings beat and names new CEO

Also covered by

5 outlets

Related articles

$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.

marketscreener.com
$ANGOMed

H.C. Wainwright cuts AngioDynamics stock price target to $18

H.C. Wainwright reduced its price target for AngioDynamics (ANGO) to $18 from $19, maintaining a Buy rating. The company reported fiscal Q1 2027 net sales of $80.9M, up 6.9% YoY, but a net loss of $7.1M. Guidance for fiscal 2027 includes revenue of $336M-$341M and adjusted EBITDA of $13M-$16M. Canaccord Genuity reiterated its Buy rating with a $20 target, citing growth in key platforms. The stock fell 23% post-earnings.

investing.com
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Polic

AngioDynamics (ANGO) announced Humana's updated Medicare Advantage coverage policy for its NanoKnife System, effective October 1, 2026. The policy applies LCD L40205 criteria for IRE technology, covering eligible patients with intermediate-risk prostate cancer and certain liver tumors. This follows recent reimbursement milestones, including CPT codes and Palmetto GBA's LCD. Humana, with 7 million members, will use LCD L40205 criteria for consistent coverage.

gurufocus.com
$ANGOHigh

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics (ANGO) reported Q1 2027 revenue growth of 7%, with the MedTech segment up 13%. Auryon saw 14.7% growth, marking 21 consecutive quarters of double-digit gains. AlphaVac revenue rose 37.4% year-over-year. The company named Eric Honer as its new CEO, effective November 2. NanoKnife received FDA approval for a BPH study, targeting a $1.9B market. Med Device segment grew 1.4%.

finance.yahoo.com